<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075226</url>
  </required_header>
  <id_info>
    <org_study_id>EDOF in POAG</org_study_id>
    <nct_id>NCT05075226</nct_id>
  </id_info>
  <brief_title>Visual Outcomes of Vivity in Patients With Well Controlled Glaucoma</brief_title>
  <official_title>Outcomes of Vivity EDOF IOL Implantation in Patients With Well Controlled OAG or OHT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maisonneuve-Rosemont Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is a progressive optic neuropathy that results in a loss of contrast sensitivity and&#xD;
      visual field if not detected and treated. When glaucoma patients undergo cataract surgery,&#xD;
      they are often not ideal candidates for many existing presbyopia correcting IOLs as they&#xD;
      reduce contrast sensitivity because of the splitting of light and are more likely to have&#xD;
      visual disturbances secondary to diffractive steps in the IOL design. This is largely because&#xD;
      of a higher rate of ocular surface disease and meibomian gland dysfunction in this patient&#xD;
      population due to the chronic utilization of topical drops. As a result of this, patients&#xD;
      with glaucoma currently receive aspheric monofocal IOLs during cataract surgery, which are&#xD;
      lenses with minimal loss of contrast sensitivity but only one point of focus (typically&#xD;
      targeted for distance). This necessitates the use of glasses for near and intermediate vision&#xD;
      and has an impact on quality of life for these patients.&#xD;
&#xD;
      The Vivity Extended Depth of Focus (EDOF) IOL is a new technology that maintains&#xD;
      uncompromised distance vision and provides improved intermediate vision correction, reducing&#xD;
      the need for glasses. This lens uses a new optical system with no diffractive steps in the&#xD;
      IOL; trials in non-glaucomatous patients have shown the rate of visual aberrations to be&#xD;
      comparable to an aspheric monofocal IOL which are currently the standard of care in patients&#xD;
      with glaucoma. There is no published data on outcomes of this IOL in patients with primary&#xD;
      open angle glaucoma (POAG) or ocular hypertension (OHT). Studies are required to evaluate the&#xD;
      clinical success of this new lens technology in glaucomatous patients. This will be the first&#xD;
      study in Canada to report clinical outcomes of the Vivity IOL in this patient cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Binocular uncorrected visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Binocular uncorrected visual acuities at 6m distance will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binocular uncorrected visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Binocular uncorrected visual acuities at intermediate distance (66cm) will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Binocular uncorrected visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Binocular uncorrected visual acuities at near distance (40cm) will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity, frequency of bothersomeness of starbursts, haloes, and glare</measure>
    <time_frame>3 months</time_frame>
    <description>Severity, frequency of bothersomeness of starbursts, haloes, and glare will be evaluated using the QUVID questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spectacle independence</measure>
    <time_frame>3 months</time_frame>
    <description>Spectacle independence will be evaluated using the IOLSAT questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP</measure>
    <time_frame>1 day</time_frame>
    <description>IOP will be measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP</measure>
    <time_frame>1 month</time_frame>
    <description>IOP will be measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP (mmHg at 1 day, 1 month and 3 months)</measure>
    <time_frame>3 months</time_frame>
    <description>IOP will be measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean refractive outcomes</measure>
    <time_frame>3 months</time_frame>
    <description>Mean refractive outcomes (error and MRSE) will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Refractive target accuracy</measure>
    <time_frame>Approximate patient follow-up time is 4 months following phacoemulsification and insertion of the study lens in the second eye. Time in between eyes will be approximately 1-2 months.</time_frame>
    <description>Percentage of eyes with an APE of 0.50D or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast sensitivity</measure>
    <time_frame>pre-operation</time_frame>
    <description>Contrast sensitivity will be evaluated using the Pelli-Robson Chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast sensitivity</measure>
    <time_frame>1 month</time_frame>
    <description>Contrast sensitivity will be evaluated using the Pelli-Robson Chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contrast sensitivity</measure>
    <time_frame>3 months</time_frame>
    <description>Contrast sensitivity will be evaluated using the Pelli-Robson Chart</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vivity Extended Depth of Focus</intervention_name>
    <description>Cataract surgery</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Prospective, single surgeon, single site (Clinique Bellevue, Montreal)&#xD;
&#xD;
          -  Sample size: Single arm (n=30) 30 bilateral patients (60 eyes total)&#xD;
&#xD;
          -  Patients who underwent bilateral cataract surgery with implantation of Vivity&#xD;
             non-toric IOL (15-25D IOL spherical power)&#xD;
&#xD;
          -  Binocular VA endpoints were evaluated at baseline and 3 months postop&#xD;
&#xD;
          -  Visual disturbances (QUVID) and spectacle independence (IOLSAT) questionnaires to be&#xD;
             administered at 3 months postop after implantation of second eye&#xD;
&#xD;
          -  Barrett Universal II and Barrett Toric IOL Calculator (for determining exclusion if T3&#xD;
             or higher is calculated) were used for IOL calculation and targeted for emmetropia&#xD;
             bilaterally for both groups&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than 18 years&#xD;
&#xD;
          -  Patients undergoing uncomplicated cataract surgery with IOL implantation&#xD;
&#xD;
          -  Patients with both eyes that calculate for IOL powers in the following ranges: 15-25D&#xD;
             spherical power (for Vivity)&#xD;
&#xD;
          -  Patients possessing with-the-rule or against-the-rule astigmatism â‰¤2.50 D&#xD;
&#xD;
          -  Well controlled OAG or OHT defined as IOP less than or equal to 18mmHg&#xD;
&#xD;
          -  Mild to moderate glaucoma as defined by MD VF loss less than 12 dB and no VF defect&#xD;
             within the central 5 degrees with 0dB or less than 15dB of both hemi-fields in the&#xD;
             central 5 degrees&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular comorbidity that might hamper post-operative visual acuity (ie. Macular&#xD;
             degeneration, macular edema, uveitis, corneal dystrophy, diabetic retinopathy)&#xD;
&#xD;
          -  Ocular trauma or zonula instability&#xD;
&#xD;
          -  Previous refractive surgery&#xD;
&#xD;
          -  Irregular corneal astigmatism and keratoconus&#xD;
&#xD;
          -  Difficulties comprehending written or spoken English or French language&#xD;
&#xD;
          -  Patients with physical or intellectual disability&#xD;
&#xD;
          -  Patients unable to fixate&#xD;
&#xD;
          -  Patients with uncontrolled glaucoma or advanced glaucoma&#xD;
&#xD;
          -  Patients that are undergoing filtration or tube surgery or MIGS devices for glaucoma&#xD;
&#xD;
          -  Patients with previous filtration or tube surgery for glaucoma&#xD;
&#xD;
          -  Patients with unreliable biometry&#xD;
&#xD;
          -  Severe dry eye disease or ocular surface disease&#xD;
&#xD;
          -  Patients where Barrett Toric Calculator recommends T5 or higher toric IOL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Paul Harasymowycz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maisonneuve-Rosemont Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Harasymowycz</last_name>
    <phone>514-256-0007</phone>
    <email>pavloh@igmtl.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique Bellevue</name>
      <address>
        <city>MontrÃ©al</city>
        <state>Quebec</state>
        <zip>H1V 1G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nataliya Khrushch</last_name>
      <phone>(514) 256-1908</phone>
      <email>nkhrushch@igmtl.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maisonneuve-Rosemont Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Paul Harasymowycz</investigator_full_name>
    <investigator_title>MD, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The plan is to publish the study in an Ophthalmology journal and present the data at national and international ophthalmological conferences (ASCRS 2021/2022, AAO 2021/2022, COS 2022, CGS 2022)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

